Magrolimab plus azacitidine vs physician’s choice for untreated TP53 -mutated acute myeloid leukemia: the ENHANCE-2 study
University of North Carolina at Chapel Hill · UNC Lineberger Comprehensive Cancer Center · +33 more institutions
Abstract
ABSTRACT: Patients with TP53-mutated acute myeloid leukemia (AML) have an extremely poor prognosis, necessitating new treatments. The global, randomized, phase 3 ENHANCE-2 trial evaluated the anti-CD47 monoclonal antibody magrolimab plus azacitidine (Magro/Aza) for previously untreated TP53-mutated AML. Patients determined ineligible for intensive therapy were randomized to receive Magro/Aza or venetoclax plus Aza (Ven/Aza); those eligible for intensive therapy were randomized to receive Magro/Aza or 7+3 induction chemotherapy. The primary end point was overall survival (OS) in the nonintensive arm. At interim analysis, nonintensive-arm OS hazard ratio (HR) between treatment groups was 1.191 (95% confidence…
Citation impact
- FWCI
- 61.90
- Percentile
- 100%
- References
- 19
Authors
22- JFJoshua F. ZeidnerCorresponding
University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center
- DADavid A. Sallman
Moffitt Cancer Center
- CRChristian Récher
Université Toulouse III - Paul Sabatier, Centre Hospitalier Universitaire de Toulouse
- NDNaval Daver
The University of Texas MD Anderson Cancer Center
- AYAnskar YH Leung
Queen Mary Hospital, University of Hong Kong - Shenzhen Hospital, University of Hong Kong
Topics & keywords
- Azacitidine
- Myeloid leukemia
- Medicine
- Internal medicine
- Leukemia
- Oncology
- Decitabine
- Myeloid